Your session is about to expire
← Back to Search
Immunotherapy + Chemotherapy for Non-Small Cell Lung Cancer
Study Summary
This trial is testing the addition of the immunotherapy drug pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there other ongoing research studies that also use Pembrolizumab?
"Pembrolizumab's first clinical trial was at City of Hope Comprehensive Cancer Center in 1997. 3404 trials have been completed since then, with 2602 presently ongoing. A large number of these active studies are based out of Brighton, Michigan."
How many people are given the opportunity to participate in this experiment?
"In order to conduct this study, we need 1210 willing and eligible participants. Potential volunteers can locate a participating medical center in their area, such as Trinity Health IHA Medical Group Hematology Oncology - Brighton in Brighton, Michigan or Oncology Hematology Associates of Saginaw Valley PC in Saginaw, Pennsylvania."
Could you please detail Pembrolizumab's side effects?
"Pembrolizumab has received a safety score of 3 from our Power team. This is due to the fact that it is a Phase 3 trial, meaning there is both efficacy and safety data available."
Can people with the relevant medical condition join this clinical trial at present?
"Yes, this information is accurate. The clinical trial in question was originally posted on June 3rd 2020 and updated November 15th of this year."
What are the main indications for Pembrolizumab?
"Pembrolizumab can help patients with hodgkin disease, as well as those that have previously received adjuvant anthracycline-containg therapy for another disease."
In how many different places is this trial taking place?
"This study is being conducted at Trinity Health IHA Medical Group Hematology Oncology - Brighton in Brighton, Michigan; Oncology Hematology Associates of Saginaw Valley PC in Saginaw, Pennsylvania; UPMC Cancer Center at UPMC Horizon in Farrell, South carolina; and 100 other locations."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger